@article {Yang5628,
	author = {Yang, Ximing J. and Tan, Min-Han and Kim, Hyung L. and Ditlev, Jonathon A. and Betten, Mark W. and Png, Carolina E. and Kort, Eric J. and Futami, Kunihiko and Furge, Kyle A. and Takahashi, Masayuki and Kanayama, Hiro-omi and Tan, Puay Hoon and Teh, Bin Sing and Luan, Chunyan and Wang, Kim and Pins, Michael and Tretiakova, Maria and Anema, John and Kahnoski, Richard and Nicol, Theresa and Stadler, Walter and Vogelzang, Nicholas G. and Amato, Robert and Seligson, David and Figlin, Robert and Belldegrun, Arie and Rogers, Craig G. and Teh, Bin Tean},
	title = {A Molecular Classification of Papillary Renal Cell Carcinoma},
	volume = {65},
	number = {13},
	pages = {5628--5637},
	year = {2005},
	doi = {10.1158/0008-5472.CAN-05-0533},
	publisher = {American Association for Cancer Research},
	abstract = {Despite the moderate incidence of papillary renal cell carcinoma (PRCC), there is a disproportionately limited understanding of its underlying genetic programs. There is no effective therapy for metastatic PRCC, and patients are often excluded from kidney cancer trials. A morphologic classification of PRCC into type 1 and 2 tumors has been recently proposed, but its biological relevance remains uncertain. We studied the gene expression profiles of 34 cases of PRCC using Affymetrix HGU133 Plus 2.0 arrays (54,675 probe sets) using both unsupervised and supervised analyses. Comparative genomic microarray analysis was used to infer cytogenetic aberrations, and pathways were ranked with a curated database. Expression of selected genes was validated by immunohistochemistry in 34 samples with 15 independent tumors. We identified two highly distinct molecular PRCC subclasses with morphologic correlation. The first class, with excellent survival, corresponded to three histologic subtypes: type 1, low-grade type 2, and mixed type 1/low-grade type 2 tumors. The second class, with poor survival, corresponded to high-grade type 2 tumors (n = 11). Dysregulation of G1-S and G2-M checkpoint genes were found in class 1 and 2 tumors, respectively, alongside characteristic chromosomal aberrations. We identified a seven-transcript predictor that classified samples on cross-validation with 97\% accuracy. Immunohistochemistry confirmed high expression of cytokeratin 7 in class 1 tumors and of topoisomerase IIÎ± in class 2 tumors. We report two molecular subclasses of PRCC, which are biologically and clinically distinct and may be readily distinguished in a clinical setting. {\textcopyright}2005 American Association for Cancer Research.},
	issn = {0008-5472},
	URL = {http://cancerres.aacrjournals.org/content/65/13/5628},
	eprint = {http://cancerres.aacrjournals.org/content/65/13/5628.full.pdf},
	journal = {Cancer Research}
}